The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brainmetastases

Oncologist

Volumn 21, Issue 2, 2016, Pages 244-251

  Moraes, Fabio Ynoe ^a,c   Taunk, Neil K ^b   Marta, Gustavo Nader ^a,c   Suh, John H ^d   Yamada, Yoshiya ^b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Oncology Center Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Brain metastasis; Stereotactic radiosurgery; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CD20 ANTIGEN; CETUXIMAB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; HISTONE DEACETYLASE; IPILIMUMAB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TRASTUZUMAB; VASCULOTROPIN; VEMURAFENIB;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LUNG CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; STEREOTACTIC RADIOSURGERY; TUMOR MICROENVIRONMENT; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; RADIOSURGERY; SECONDARY;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RADIOSURGERY;

EID: 84957583663     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0293     Document Type: Article

References (69)

1. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533–540.
2. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996;7:337–344.
3. Sundermeyer ML, Meropol NJ, Rogatko A et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5:108–113.
4. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999;13: 941–954, 957–961; discussion 961–962, 969.
5. Alexander E 3rd, Moriarty TM, Davis RB et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995;87:34–40.
6. Flickinger JC, Kondziolka D, Lunsford LD et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994;28:797–802.
7. Pirzkall A, Debus J, Lohr F et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998;16: 3563–3569.
8. Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 2014;32:2886–2893.
9. Sheehan JP, Yen CP, Lee CC et al. Cranial stereotactic radiosurgery: Current status of the initial paradigm shifter. J Clin Oncol 2014;32: 2836–2846.
10. Brown PD, Brown CA, Pollock BE et al. Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery 2002;51: 656–665; discussion 665–667.
11. Chang EL, Selek U, Hassenbusch SJ 3rd et al. Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005;56:936–945; discussion 936–945.
12. Gaspar LE, Scott C, Murray K et al.Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001–1006.
13. Suh JH. Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 2010;362:1119–1127.
14. Yamamoto M, Kawabe T, Sato Y et al. A casematched study of stereotactic radiosurgery for patients withmultiple brain metastases: Comparing treatment results for 1-4 vs $ 5 tumors: Clinical article. J Neurosurg 2013;118:1258–1268.
15. Serizawa T, Yamamoto M, Sato Y et al. Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional prospective study. J Neurosurg 2010;113(suppl):48–52.
16. Shaw E, Scott C, Souhami L et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000;47:291–298.
17. Balagamwala EH, Chao ST, Suh JH. Principles of radiobiology of stereotactic radiosurgery and clinical applications in the central nervous system. Technol Cancer Res Treat 2012;11:3–13.
18. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRSand SBRT:Aremorethan the5Rs involved? Int J Radiat Oncol Biol Phys 2014;88: 254–262.
19. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005;8:89–91.
20. Kolesnick R, Fuks Z. Radiation and ceramideinduced apoptosis. Oncogene 2003;22:5897–5906.
21. Park C, Papiez L, Zhang S et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70: 847–852.
22. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 2013;105:256–265.
23. Wallner PE, Steinberg ML, McBride WH et al. A fork in the road: Choosing the path of relevance. Int J Radiat Oncol Biol Phys 2015;92:214–216.
24. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.NEngl JMed2006;354:567–578.
25. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006;16:2–9.
26. Lin NU.Targetedtherapies in brainmetastases. Curr Treat Options Neurol 2014;16:276.
27. Zeng J, Baik C, Bhatia S et al. Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol 2014;15:e426–e434.
28. Shen Y, Ruan M, Luo Q et al. Brain metastasis from follicular thyroid carcinoma: Treatment with sorafenib. Thyroid 2012;22:856–860.
29. Sanna G, Petralia G, Cossu RoccaMet al. Long survival in a patient with brain metastases from breast cancer. Clin Med Oncol 2008;2:103–108.
30. Ruzevick J, Nicholas S, Redmond K et al. A patient with HIV treated with ipilimumab and stereotactic radiosurgery formelanomametastases to the brain. Case Rep Oncol Med 2013;2013: 946392.
31. Carlson JA, Nooruddin Z, Rusthoven C et al. Trastuzumab emtansine and stereotactic radiosurgery: An unexpected increase in clinically significant brain edema. Neuro-oncol 2014;16:1006–1009.
32. Staehler M, Haseke N, Nuhn P et al. Simultaneous anti-angiogenic therapy and singlefraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 2011;108: 673–678.
33. Cochran DC, Chan MD, Aklilu M et al.The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012;116: 978–983.
34. Knisely JP, Yu JB, Flanigan J et al. Radiosurgery for melanoma brain metastases in the ipilimumab eraand the possibility of longer survival. JNeurosurg 2012;117:227–233.
35. Silk AW, Bassetti MF, West BT et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013;2:899–906.
36. Vickers MM, Al-Harbi H, Choueiri TK et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: Results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013;11: 311–315.
37. Mathew M, Tam M, Ott PA et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.MelanomaRes 2013; 23:191–195.
38. Yomo S, Hayashi M, Cho N. Impacts of HER2- overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer. J Neurooncol 2013; 112:199–207.
39. Tazi K, Hathaway A, Chiuzan C et al. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 2015;4:1–6.
40. Tam M, Narayana A, Raza S et al. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery. Med Oncol 2014;31:832.
41. Narayana A, Mathew M, Tam M et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013;113: 411–416.
42. Kiess AP, Wolchok JD, Barker CA et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015;92:368–375.
43. Thomas Jefferson University. Ipilimumab and whole-brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases. ClinicalTrials.gov. 2015. Available at https://clinicaltrials.gov/ct2/show/NCT01703507. Accessed July 21, 2015.
44. University Health Network. Stereotactic radiosurgery with sunitinib for brain metastases. ClinicalTrials.gov. 2015. Available at https://clinicaltrials.gov/ct2/show/NCT00981890. Accessed July 21, 2015.
45. University of California, San Francisco. A phase 2 prospective trial of dabrafenib with stereotactic radiosurgery in BRAFV600E melanoma brain metastases. ClinicalTrials.gov. 2015. Available at https://clinicaltrials.gov/ct2/show/ NCT01721603. Accessed July 21, 2015.
46. Vanderbilt-Ingram Cancer Center. Sorafenib tosylate and stereotactic radiosurgery in treating patients with brain metastases. ClinicalTrials.gov. 2015. Available at https://clinicaltrials.gov/ct2/show/NCT01276210. Accessed July 21, 2015.
47. Sperduto PW, Wang M, Robins HI et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013;85:1312–1318.
48. Wang Y, Wang E, Pan L et al. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neurooncol 2014;119:369–376.
49. Preusser M, Capper D, Ilhan-Mutlu A et al. Brain metastases: Pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123: 205–222.
50. Yin W, Jiang Y, Shen Z et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PloS One 2011;6: e21030.
51. Musolino A, Ciccolallo L, Panebianco M et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: Epidemiological and clinical data from a population-based cancer registry study. Cancer 2011;117:1837–1846.
52. Deibert CP, Ahluwalia MS, Sheehan JP et al. Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery. J Neurooncol 2013;115:217–223.
53. Boothe D, Young R, Yamada Y et al. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-oncol 2013;15:1257–1263.
54. Le Scodan R, Jouanneau L, Massard C et al. Brain metastases from breast cancer: Prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2011;11:395.
55. Gerber NK, Yamada Y, Rimner A et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 2014;89:322–329.
56. Welsh JW, Komaki R, Amini A et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013;31: 895–902.
57. Fife KM, Colman MH, Stevens GN et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22: 1293–1300.
58. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAFmutant melanoma metastatic to the brain (BREAKMB): Amulticentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087–1095.
59. Dummer R, Goldinger SM, Turtschi CP et al. Vemurafenib in patients with BRAF(V600) mutationpositive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer 2014;50:611–621.
60. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012;13:459–465.
61. Schartz NE, Farges C, Madelaine I et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010;20:247–250.
62. Ly D, Bagshaw HP, Anker CJ et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 2015;123: 395–401.
63. (P011) stereotactic radiosurgery and BRAF inhibitor therapy for melanoma brain metastases is associated with increased risk for radiation necrosis. Oncology (Williston Park) 2015; 29(suppl 1).
64. Liebner DA, Walston SA, Cavaliere R et al. Radiation necrosis mimicking rapid intracranial progression ofmelanomametastasis intwopatients treated with vemurafenib. Melanoma Res 2014;24: 172–176.
65. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep 2011;13:50–56.
66. Lin NU, Lee EQ, Aoyama H et al. Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol 2015;16: e270–e278.
67. Lin NU, Lee EQ, Aoyama H et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013;14:e396–e406.
68. Lin NU, Wefel JS, Lee EQ et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013;14:e407–e416.
69. Jagsi R, Wilson LD. Research funding for radiation oncology: An unfortunately small sliver of an inadequate pie. Int J Radiat Oncol Biol Phys 2013;86:216–217.